63.78
63.78 (0.24%)
As of Mar 06, 2024
Legend Biotech Corp [LEGN]
Source:
Company Overview
We are primarily a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 1,000 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Our lead product candidate, ciltacabtagene autoleucel, or cilta-cel (referred to as LCAR- B38M for purposes of our LEGEND-2 trial), is a chimeric antigen receptor, or CAR, T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc., or Janssen, for the treatment of multiple myeloma, or MM.
Country | Cayman Islands |
Headquarters | somerset, new jersey |
Phone Number | 732-317-5050 |
Industry | manufacturing |
CEO | Ying Huang, Ph.D. |
Website | legendbiotech.com |